Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

617.80INR
10:26am IST
Change (% chg)

Rs-2.55 (-0.41%)
Prev Close
Rs620.35
Open
Rs619.90
Day's High
Rs621.95
Day's Low
Rs615.25
Volume
297,961
Avg. Vol
2,625,722
52-wk High
Rs696.60
52-wk Low
Rs316.25

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

BUZZ-India's Biocon hits record high after FDA approves partner's drug

** Shares of Biocon Ltd rise as much as 6.4 pct to record high of 696.60 rupees

05 Jun 2018

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

05 Jun 2018

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)

05 Jun 2018

FDA approves Mylan's biosimilar to Neulasta

June 4 The U.S. Food And Drug Administration on Monday approved a drug from Mylan NV as the first biosimilar to Amgen's drug Neulasta to help reduce the risk of infection during cancer treatment.

05 Jun 2018

BUZZ-India's Biocon falls; plant gets observations from US FDA, European regulator

** Biopharmaceutical company Biocon Ltd's shares fall as much as 5.1 pct to 630 rupees, its biggest daily pct loss since Feb. 6

03 May 2018

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

02 May 2018

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

26 Apr 2018

Biocon fourth-quarter profit rises 2.2 percent

Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

26 Apr 2018

India's Biocon Q4 profit rises 2.2 pct

April 26 Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

26 Apr 2018

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

11 Apr 2018

Earnings vs. Estimates

No consensus analysis data available.